Clinical trials: Cognitive Disorder
Dementia, Mild Cognitive Impairment
In-Home Technology for Caregivers of People With Dementia and Mild Cognitive Impairment: Rural Homes
This study aims to develop, evaluate, and commercialize an in-home supportive technology that is designed to alleviate anxiety, burden, and loneliness in spousal and familial caregivers of individuals with Alzheimer's disease…
- Conditions
- Dementia, Mild Cognitive Impairment, Alzheimer Disease
- Trial name
- NCT05159583
- Testing
- In-Home Technology System, Limited In-Home Technology
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- University of California, Berkeley
Alzheimer's Disease
Practice Effects and Amyloid Imaging Using 18F-PIB or Flutemetamol PET and FDG-PET
Alzheimer's disease (AD) is the most common cause of progressive cognitive decline in the United States. AD is characterized by severe impairments in learning, memory and other cognitive abilities that significantly interfere…
- Trial name
- NCT01202994
- Testing
- 18F-Flutemetamol
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- University of Utah
Major Depressive Disorder
Therapist-Guided Smartphone-Delivered CBT for MDD
We are testing a smartphone app that provides therapy for depression. Participants will also receive short weekly virtual appointments with a therapist.
- Trial name
- NCT05386329
- Testing
- Mindset: Therapist-guided smartphone-delivered CBT
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Massachusetts General Hospital
Multiple Sclerosis, Neurological Disorder
Cognitive Remediation Augmented With Transcranial Direct Current Stimulation (tDCS)
The proposed study will test the feasibility and tolerability of transcranial direct current stimulation (tDCS) added to a cognitive remediation program in n=100 adults.
- Trial name
- NCT03049969
- Testing
- tDCS stimulation
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- NYU Langone Health
Obsessive-Compulsive Disorder
Dealing With Intrusive Thoughts in OCD - a Comparison of Detached Mindfulness and Cognitive Restructuring
The purpose of this study is to assess and compare the overall efficacy and differential effects of detached mindfulness and cognitive restructuring in the treatment of patients with obsessive-compulsive disorder.
- Trial name
- NCT03002753
- Testing
- detached mindfulness, cognitive restructuring
- Where
- Germany
- Volunteers
- 43 people
- Sponsor
- Christoph-Dornier-Stiftung für Klinische Psychologie
Fragile X Syndrome, FXS
A 2-Period Crossover Study of BPN14770 in Adults Males With Fragile X Syndrome
This is a single-center, randomized, double-blind, 2-period crossover study to explore the effects of BPN14770 on cognitive function and behavior in subjects with Fragile X Syndrome.
- Conditions
- Fragile X Syndrome, FXS, Fra(X) Syndrome
- Trial name
- NCT03569631
- Testing
- BPN14770
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Tetra Discovery Partners
Alzheimer's Disease
Clinical Pharmacology of p38 MAP Kinase Inhibitor, VX-745, in Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD
This study will assess the effects of VX-745 on markers of disease in the central nervous system of patients with MCI due to AD or with mild AD.
- Trial name
- NCT02423200
- Testing
- VX-745
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- EIP Pharma Inc
Prostate Cancer
Facilitating Participation in a Prostate Cancer Risk Assessment Program
The purpose of this study was to examine whether a cognitive-affective preparation was more beneficial, in general, and more specifically for certain subgroups, such as African-American men and individuals with high monitoring…
- Trial name
- NCT02126319
- Testing
- Cognitive Affective preparation, General Health Education
- Where
- United States
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- Fox Chase Cancer Center
Dementia, Alzheimer Type
A Phase II Study to Assess the Safety, Tolerability and Efficacy of Xanamem™ in Subjects With Mild Dementia Due to AD (XanADu)
This XanADu Phase II study in mild Alzheimer's Disease (AD) is to assess the safety, tolerability and efficacy of Xanamem in subjects with mild dementia due to Alzheimer's Disease.
- Trial name
- XanADu (NCT02727699)
- Testing
- Xanamem™
- Where
- 25 sites in United States, Australia and 1 more
- Volunteers
- 185 people
- Sponsor
- Actinogen Medical
Hematopoietic Stem Cell Transplantation, Cognitive Impairments
The "Light for the Brain" Study
Cognitive impairment (such as memory problems) due to cancer and its treatment can interfere with quality of life and can linger long after treatment has ended, yet research examining cognitive rehabilitation approaches has…
- Conditions
- Hematopoietic Stem Cell Transplantation, Cognitive Impairments, Sleep, Depression
- Trial name
- NCT02677987
- Testing
- Intervention systematic light exposure, Comparison systematic light exposure
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Northwestern University
Huntington's Disease
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 443139 in Participants With Early Manifest Huntington's Disease
This study tested the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of ISIS 443139 administered intrathecally to adult participants with early manifest Huntington's Disease.
- Trial name
- NCT02519036
- Testing
- ISIS 443139 10 mg, ISIS 443139 30 mg, ISIS 443139 60 mg
- Where
- 9 sites in Canada, Germany and 1 more
- Volunteers
- 46 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Post Traumatic Headache
Naratriptan for the Treatment of Post Traumatic Headache Associated With Cognitive Dysfunction
The purpose of this study is to determine whether naratriptan, a medication approved for treatment of migraine, is effective in the treatment of post traumatic headache associated with cognitive dysfunction.
- Trial name
- NCT00487578
- Testing
- naratriptan HCl
- Where
- 3 sites in United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Cady, Roger, M.D.
Alzheimer's Disease
A Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Participants With Early Alzheimer's Disease
This study seeks to evaluate the efficacy and safety of ABBV-8E12 in participants with early Alzheimer's disease (AD).
- Trial name
- NCT02880956
- Testing
- ABBV-8E12
- Where
- 68 sites in United States, Australia and 9 more
- Volunteers
- 453 people
- Sponsor
- AbbVie
Huntington's Disease
Study in PRE-manifest Huntington's Disease of Coenzyme Q10 (UbiquinonE) Leading to Preventive Trials (PREQUEL)
To establish the tolerability of treatment with 600, 1200 or 2400 mg per day of coenzyme Q10 in pre-manifest participants carrying the CAGn expansion for Huntington's Disease (HD).
- Trial name
- PREQUEL (NCT00920699)
- Testing
- CoQ10
- Where
- 13 sites in United States
- Volunteers
- 90 people
- Sponsor
- Johns Hopkins University
Depression
Treatment of Depression in Acute Coronary Syndrome (ACS) Patients
Emotional states of depression in association with ischemic heart diseases, such as myocardial infarction or unstable angina, are risk factors for subsequent cardiac events and mortality.
- Trial name
- TREATED-ACS (NCT00998400)
- Testing
- CBT in combination with WBT and life style modification
- Where
- 2 sites in Italy
- Volunteers
- 100 people
- Sponsor
- University of Bologna
Parkinson's Disease
Cognitive Rehabilitation in Parkinson's Disease
We are testing a computer game-style rehabilitation program for people with Parkinson's disease (PD). People with PD often have difficulty with motor planning, such as initiating or starting movements.
- Trial name
- NCT01085968
- Testing
- PC based training
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Schizophrenia, Psychosis
Non-Invasive Direct Current Stimulation for Cognition in Schizophrenia
This study proposes to assess the effect of trans-cranial direct current stimulation (tDCS) on cognitive control, working memory, functional, clinical, and cognitive outcomes in schizophrenia patients.
- Trial name
- NCT02739347
- Testing
- Active Trans-cranial direct-current stimulation
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Baylor College of Medicine
Alzheimer's Disease
Safety Study of R(+)Pramipexole to Treat Early Alzheimer's Disease
By doing this study, researchers will examine the safety and tolerability of R-pramipexole in participants with Alzheimer's disease.
- Trial name
- NCT01388478
- Testing
- R-pramipexole
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Virginia Commonwealth University
Social Anxiety Disorder
D-Cycloserine Enhancement of Exposure in Social Phobia
The purpose of this study is to test a drug called d-cycloserine to see if it can help people with a condition called social phobia.
- Trial name
- NCT00633984
- Testing
- Cognitive Behavioral Group Therapy (CBGT), D-Cycloserine
- Where
- United States
- Volunteers
- 169 people
- Sponsor
- Massachusetts General Hospital
Early Manifest Huntington Disease
A Dose Range Finding Study With Open-Label Extension to Evaluate the Safety of Oral LMI070/Branaplam in Early Manifest Huntington's Disease
This is the first study of branaplam in adults with Huntington's Disease (HD) to determine the correct dose required to lower mutant huntingtin protein (mHTT) levels in the cerebrospinal fluid (CSF) to a degree expected to be…
- Trial name
- VIBRANT-HD (NCT05111249)
- Testing
- Branaplam
- Where
- 12 sites in Canada, France and 3 more
- Volunteers
- 26 people
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.